Clinical trials: Chemotherapy Induced Nausea and Vomiting
Nausea and Vomiting, Chemotherapy-Induced
A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults
Casopitant may affect liver enzymes that metabolize ketoconazole. This study is designed to test the safety and the extent of the Casopitant affect on ketoconazole levels in healthy human subjects.
- Trial name
- NCT00460707
- Testing
- Casopitant 150 mg, Ketoconazole, Casopitant 50 mg
- Where
- 3 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Nausea With Vomiting Chemotherapy-Induced
BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron
Patients undergoing either an autologous or allogeneic hematopoietic stem cell transplant (HSCT) and receiving preparative chemotherapy experience a considerable amount of chemotherapy-induced nausea and vomiting (CINV).
- Trial name
- NCT04150614
- Testing
- Granisetron Transdermal Patch, Intravenous Dexamethasone, Ondansetron
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Illinois at Chicago
Nausea With Vomiting Chemotherapy-Induced
Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting
Phase 2 study to compare efficacy, safety and PK of palonosetron, a long acting 5-HT3 receptor antagonist, by buccal film delivery compared to iv injection for chemotherapy induced nausea or vomiting (CINV).
- Trial name
- NCT04592198
- Testing
- Palonosetron Hydrochloride Buccal Film 0.25 Mg, Palonosetron Hydrochloride Buccal Film 0.5 Mg, Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Xiamen LP Pharmaceutical Co., Ltd
Chemotherapy-induced Nausea and Vomiting
Effect of tDCS of the Motor Cortex on Chemotherapy Induced Nausia and Vomiting
this work is looking for the effect of tDCS of the motor cortex on the chemotherapy induced nausea and vomiting in cancer breast patients
- Trial name
- NCT03405324
- Testing
- tDCS
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Shereen Mamdouh
Nausea
Pregabalin for the Prevention of Chemotherapy Induced Nausea and Vomiting
phase II randomized, double-blind, placebo-controlled trial to investigate whether pregabalin can improve the complete control of nausea and vomiting (primary end point)
- Trial name
- NCT04181346
- Testing
- Pregabalin
- Where
- Brazil
- Volunteers
- 82 people
- Sponsor
- Faculdade de Medicina do ABC
Nausea, Vomiting
Auriculotherapy and Acupuncture's Treatment for Chemotherapy-induced Nausea and Vomiting (CINV)
The management of chemotherapy-induced nausea and vomiting (CINV) has evolved in recent years and became less frequent. CINV include early (occurring within 24 hours of chemotherapy administration) and delayed (occurring within 4…
- Trial name
- NVCI (NCT02767791)
- Testing
- Acupuncture, Auriculotherapy
- Where
- 5 sites in France
- Volunteers
- 116 people
- Sponsor
- Hopital Foch
Breast Cancer
Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile
The objectives of this study are to determine if pharmacogenetic (PG) analysis of an individual enable optimal selection of antiemetic regimen for patients undergoing the first cycle of AC (Adriamycin + Cyclophosphamide) or FEC…
- Trial name
- NCT07455955
- Testing
- Standard antiemetic regimen or Olanzapine antiemetic regimen
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong
Chemotherapy-induced Nausea and Vomiting
Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers
Antiemetic therapies have improved in recent years, but chemotherapy-induced nausea and vomiting (CINV) are still common and are among the most distressing side effects of chemotherapy.
- Trial name
- NCT03245918
- Testing
- Aprepitant Capsule 125 MG, Aprepitant oral suspension 20 mg/mL
- Where
- Canada
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- The Hospital for Sick Children
Acute Leukemia
Nausea and Vomiting in Children Receiving Chemotherapeautic Monotherapy
Chemotherapy induced nausea is a common side effect for children undergoing chemotherapy. Furthermore, chemotherapy-induced vomiting is a major factor limiting quality of life during treatment reported by paediatric cancer…
- Trial name
- NCT01661413
- Where
- Canada
- Volunteers
- 88 people
- Sponsor
- The Hospital for Sick Children
Malignant Neoplasm
Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant
This phase II trial studies how well netupitant and palonosetron hydrochloride work in preventing chemotherapy induced nausea and vomiting in patients with cancer undergoing BEAM conditioning regimen before stem cell transplant.
- Trial name
- NCT03097588
- Testing
- Netupitant, Palonosetron Hydrochloride, Questionnaire Administration
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer Female, Acupuncture
Electric Stimulation on Nausea and Vomit Chemotherapy Induced
Chemotherapy induces nausea and vomit for some large patients. But, some chemotherapy protocol has a high indices of the incidence as observed in a combination of Anthracycline and Cyclophosphamide (AC).
- Trial name
- TENS-NV (NCT03145727)
- Testing
- Low Frequency Group, High Frequency Group
- Where
- 2 sites in Brazil
- Volunteers
- 84 people
- Sponsor
- Federal University of Health Science of Porto Alegre
Chemotherapy Induced Nausea and Vomiting
Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 6 to 12 years.
- Trial name
- NCT01596413
- Testing
- Sancuso, IV granisetron
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
The goal of this clinical research study is to learn if adding dronabinol in combination with the standard of care (dexamethasone and palonosetron) can better help to control nausea and vomiting in patients receiving…
- Trial name
- NCT00553059
- Testing
- dexamethasone, dronabinol, palonosetron hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Electro-acupuncture, Chemotherapy-induced Nausea and Vomiting
The Comparative Study on the Efficacy and Safety of Single Acupoint and Matching Acupoints
The purpose of this study is to clarify whether the matching acupoints are more effective than a single point by electro-acupuncture in the management of chemotherapy-induced nausea and vomiting.
- Trial name
- NCT03061396
- Testing
- Matching points PC6+CV12, Single points PC6
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Tianjin University of Traditional Chinese Medicine
Breast Cancer
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients
The Olanzapine Regimen will be superior to the Standard Regimen, as measured by the proportion of patients with Complete Response in the 120 hours following AC chemotherapy.
- Trial name
- NCT03079219
- Testing
- Experimental drug: Aprepitant, Experimental drug: Ondansetron, Experimental drug: Dexamethasone
- Where
- Hong Kong
- Volunteers
- 120 people
- Sponsor
- CCTU
Chemotherapy-induced Nausea and Vomiting
An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC
This prospective, multicenter, non-comparative, open-label trial design aims to evaluate the efficacy and safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in preventing nausea and vomiting induced by…
- Trial name
- NCT07482891
- Testing
- Fosrolapitant and Palonosetron Hydrochloride for Injection, Dexamethasone, Olanzapine
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai 6th People's Hospital
Carcinoma, Non-small Cell Lung
Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers
Aprepitant is an oral neurokinin-1(NK-1) antagonist which is widely used for the prevention of chemotherapy-induced nausea and vomiting(CINV), it is metabolized by CYP34A, however, up to now it was still unknown the CINV control…
- Trial name
- NCT02161991
- Testing
- Aprepitant
- Where
- China
- Volunteers
- 244 people
- Sponsor
- Hunan Province Tumor Hospital
Chemotherapy Induced Nausea Vomiting
Combination of Netupitant and Palonosetron (Akynzeo®) in the Treatment of Refractory CINV
Prevention and control of Chemotherapy-Induced Nausea and Vomiting (CINV) are most important in treatment of cancer patients. CINV is one of the most distressing severe side effects of cancer treatment and can have a significant…
- Trial name
- CINV (NCT03008213)
- Testing
- Netupitant and Palonosetron
- Volunteers
- 4 people
- Sponsor
- Joseph Ma
Vomiting, Nausea
A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea
The purpose of this study is to compare the efficacy and safety of ramosetron plus dexamethasone injection with granisetron plus dexamethasone injection for the prevention of chemotherapy-induced vomiting and nausea.
- Trial name
- NCT00272285
- Testing
- Ramosetron, Granisetron
- Where
- 2 sites in Taiwan
- Volunteers
- 287 people
- Sponsor
- Astellas Pharma Inc
Chemotherapy-Induced Nausea and Vomiting
A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)
This study will assess the bioequivalence of single oral doses of aprepitant (MK0869) to a single intravenous infusion of fosaprepitant (MK0517) and also determine the effect of food on the bioavailability of oral aprepitant.
- Trial name
- NCT00945321
- Testing
- aprepitant 165 mg, Comparator: aprepitant 185 mg, Comparator: fosaprepitant 150 mg
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC